by David Kent | Jun 26, 2015
. I just sat through one of the simplest and most logical talks. Dr. Elly Tanaka, from Heidelberg, took the stage in the plenary session and described an incredible set of data that her lab has generated to understand the molecules involved in limb regeneration – a...
by Mark Curtis | Jun 24, 2015
. Welcome to your Update from the Clinic for the month of May. StemCells announced positive topline results from a Phase I/II study in spinal cord injury. Kite Pharma treated its first patient in a Phase I/II study investigating an anti-CD19 CAR T construct in...
by Mark Curtis | Jun 22, 2015
. Welcome to your deal review for the month of May. Juno Therapeutics was active, forming a strategic research collaboration with Fate Therapeutics and acquiring Stage Cell Therapeutics. Adaptimmune decided it would take advantage of the ongoing initial public...
by David Kent | Jun 16, 2015
. Last week the German Stem Cell Network (SCN) released three videos on the current and future possibilities of stem cells. The videos feature three top tier scientists in the field – Andreas Trumpp, Magdalena Gotz and Anthony Ho – and treat viewers to their...
by Mark Curtis | May 27, 2015
. Welcome to your deal review for the month of April. There is no update yet on the fate of the Cellular Dynamics International/Fujifilm deal, but it appears that CDI made some effort to solicit offers from alternative bidders. Aduro made headlines, though, closing a...
by Mark Curtis | May 25, 2015
. Welcome to your Update from the Clinic for the month of April. Mesenchymal stem cells took a hit as Athersys’ MultiStem came up short, missing its primary endpoint in a Phase 2 study investigating the cells for ischemic stroke. Juno Therapeutics continues to turn...
Comments